In addition, followed by EGFR-TKI therapy, the lesions of NSCLC patients in the effective group were significantly reduced, the growth and metastasis of malignant tumors were inhibited, and the relative expression of serum miR-183 might be affected. This evidence concerns the gene EGFR and non-small cell lung carcinoma.